Clinical trial
A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With…
NCT00215956 · H. Lee Moffitt Cancer Center and Research Institute, Other · Completed
Key facts
| NCT number | NCT00215956 |
|---|---|
| Title | A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Carcinoma |
| Official title | A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Carcinoma |
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Rectal Neoplasms |
| Intervention type | Drug, Procedure |
| Interventions | topotecan, radiation, surgery |
| Enrollment | 31 |
| Start date | Nov 1, 2001 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Sep 22, 2005 |
| Last update posted | Dec 23, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: